• IDS Gains FDA Clearance for a New Specialist Assay

News & Views

IDS Gains FDA Clearance for a New Specialist Assay

Immunodiagnostic Systems Holdings plc, a leading producer of diagnostic testing kits and automated systems for the clinical and research markets, has received clearance from the US Food and Drugs Administration (FDA) for its Intact PTH automated immunoassay kit. The Intact PTH assay is intended for the quantitative determination of parathyroid hormone levels in human serum or plasma on the IDS-iSYS automated analyser. Results of the tests are to be used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism, which will enable doctors to more accurately diagnose parathyroid disease and to monitor patients undergoing renal dialysis and other diseases caused by calcium homeostasis. Ian Cookson, CEO of IDS, said: “As part of our strategy to diversify our product offering, we are pleased to have received FDA clearance for this important assay. The ability to offer Intact PTH on the IDS-iSYS in the US complements our automated 25 Hydroxy Vitamin D assay
and will further facilitate the placement of IDS- iSYS systems.”


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

Nano Tech 2025

Jan 29 2025 Tokyo, Japan

View all events